<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>380-NIMODIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>380-NIMODIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>380-NIMODIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
